|Download document||Draft guideline on the role of the pathological Complete Response as an endpoint in neoadjuvant breast cancer studies|
|Status||draft: consultation open|
|Consultation start date||28/04/2014|
|Consultation end date||31/07/2014|
|Email address for firstname.lastname@example.org|
Neoadjuvant chemotherapy is commonly used in locally advanced breast cancer (LABC) patients to facilitate breast conserving surgery (Romero et al. Annals of Oncology 24: 655-661, 2013). Currently, disease-free survival (DFS) is considered to be an appropriate endpoint for treatment effect and as a surrogate endpoint for overall survival (OS) (EMA/CHMP/205/95/Rev.4).